NANO-TARGETED DELIVERY OF PROTEASE, POLYMERASE INHIBITORS WITH OR WITHOUT IMMUNE MODULATORS IN THE TREATMENT OF HEPATITIS C

摘要

This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.

主权项

1. A composition, comprising:
a protease inhibitor (Compound A); a polymerase inhibitor (Compound B); anti-fibrotic/anti-hemolytic agents (Compound C) comprising a combination of naturally driven Polyphenol/Thiols; and Non-anticoagulant GAGs (Compound D) in Nanoformulation platforms.